Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Diabetes Mellitus, Type 2 1

Interventions

Pioglitazone 4Sulfonylurea Compounds 3Sitagliptin Phosphate 3Resistance Training 3Metformin 3Dipeptidyl-Peptidase IV Inhibitors 3Vildagliptin 2Sodium-Glucose Transporter 2 Inhibitors 2Nutritional Status 2Glucagon-Like Peptide-1 Receptor Agonists 2Blood Specimen Collection 2voglibose 1saxagliptin 1repaglinide 1miglitol 1metahexamide 1meglitinide 1mazdutide 1glymidine 1glisoxepide 1gliquidone 1glimepiride 1glibornuride 1desaminopancreozymin octapeptide 1alogliptin 1Urine Specimen Collection 1Troglitazone 1Tolbutamide 1Tolazamide 1Thiazolidinediones 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Diabetes Mellitus, Type 2 × repaglinide × Clear all
NCT02475499 2016-03-14

Incretin-based Drugs and Pancreatic Cancer

Canadian Network for Observational Drug Effect Studies, CNODES

Completed
886,172 enrolled
Gastrointestinal

Diabetes Mellitus, Type 2, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡